Guidelines on the use of therapeutic apheresis in clinical practice-Evidence-based approach from the apheresis applications committee of the American Society for Apheresis

The American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. Beginning with the 2007 ASFA Special Issue (fourth edition), the subcommittee has incorporated systematic review and evidence‐based approac...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical apheresis Vol. 25; no. 3; pp. 83 - 177
Main Authors Szczepiorkowski, Zbigniew M., Winters, Jeffrey L., Bandarenko, Nicholas, Kim, Haewon C., Linenberger, Michael L., Marques, Marisa B., Sarode, Ravindra, Schwartz, Joseph, Weinstein, Robert, Shaz, Beth H.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 2010
Subjects
apheresis
Blood Component Removal - methods
Blood Component Removal - standards
categories
Disease
evidence based
Evidence-Based Medicine - standards
Humans
immunoadsorption
indications
leukocytapheresis
Methods
photopheresis
plasma exchange
Societies
Therapeutics - standards
Online AccessGet full text
ISSN0733-2459
1098-1101
1098-1101
DOI10.1002/jca.20240

Cover

More Information
Summary:The American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. Beginning with the 2007 ASFA Special Issue (fourth edition), the subcommittee has incorporated systematic review and evidence‐based approach in the grading and categorization of indications. This Fifth ASFA Special Issue has further improved the process of using evidence‐based medicine in the recommendations by refining the category definitions and by adding a grade of recommendation based on widely accepted GRADE system. The concept of a fact sheet was introduced in the Fourth edition and is only slightly modified in this current edition. The fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis. The article consists of 59 fact sheets devoted to each disease entity currently categorized by the ASFA as category I through III. Category IV indications are also listed. J. Clin. Apheresis, 2010. © 2010 American Society for Apheresis
Bibliography:Disclaimer: This document contains information prepared by the American Society for Apheresis (ASFA) for the apheresis community and those who request the use of therapeutic apheresis. Although due care has been used in the preparation of this document, ASFA makes no representation or warranty, express or implied that it is free from errors or omissions, or that it is exhaustive, and expressly disclaims all warranties, including but not limited to, warranties as to the information's quality or fitness for a particular purpose. The information contained herein is not intended to supplant the clinical judgment of qualified medical professionals. ASFA and its directors, officers, employees, members, representatives, and agents accept no liability for any loss, cost, expense, injury, or damages, whether direct, indirect, incidental, consequential, special, or other, arising from the application of the information contained in this document for patient care or any other use. The accuracy of the information contained herein is subject to changes in circumstances after the time of publication. ASFA accepts no responsibility for the accuracy and reliability of information provided by third parties.
ArticleID:JCA20240
ark:/67375/WNG-JL6M29LW-L
istex:B558B1CC235DC928E00B3385AC15E18F9A4AB31D
All authors contributed equally to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Instructional Material/Guideline-3
content type line 23
ISSN:0733-2459
1098-1101
1098-1101
DOI:10.1002/jca.20240